Aurobindo Pharma Ltd has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Amoxicillin for oral suspension.

The drug is the generic equivalent to the reference listed drug product (RLD) Amoxicillin for oral suspension of Teva Pharmaceutical Industries Ltd and is indicated in the treatment of infections due to susceptible Betalactamase-negative strains of the designated microorganisms.

The product had a market size of approximately $19 million for the 12 months ending July 2014, according to IMS.

"This Abbreviated New Drug Application (ANDA) was approved out of Unit XII, Semi-Synthetic Penicillin formulation facility here,” the Hyderabad-based company said in a release issued here on Tuesday.

comment COMMENT NOW